New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 23, 2018 - Sun Pharma announced the FDA approval of Yonsa (abiraterone), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone.
Download PDF
Return to publications
